| [Table_Rank] | 投资评级：买入（维持） | | | --- | --- | --- | | 报告日期： | 2025-05-05 | | | [Table_BaseData] 收盘价（元） | | 23.29 | | 近 12 个月最高/最低（元） | 27.85/15.97 | | --- | --- | | 总股本（百万股） | 3,615 | | 流通股本（百万股） | 3,615 | | 流通股比例（%） | 100.00 | | 总市值（亿元） | 842 | | 流通市值（亿元） | 842 | [公司价格与沪深 Table_Chart] 300 走势比较 北方稀土（ [Table_StockNameRptType] 600111） 公司点评 产销量大幅增长，持续优化生产 [Table_Author] 分析师：许勇其 执业证书号：S0010522080002 邮箱：xuqy@hazq.com 分析师：牛义杰 执业证书号：S0010524050005 邮箱：niuyj@hazq.com -26% -7% 12% 30% 49% 4/24 7/24 10/24 1/25 4/25 北 ...

-30% -10% 10% 30% 50% 70% 90% 4/24 7/24 10/24 1/25 4/25 生益科技 沪深300 [Table_Author] 分析师：陈耀波 执业证书号：S0010523060001 邮箱：chenyaobo@hazq.com 分析师：李元晨 [Table_StockNameRptType] 生益科技（600183） 公司点评 生益科技：业绩高速成长，充分受益于算力时代 [Table_Rank] 投资评级：买入（维持） 报告日期：2025-05-05 | [Table_BaseData] 收盘价（元） | 24.29 | | --- | --- | | 近 12 个月最高/最低（元） | 35.38/16.47 | | 总股本（百万股） | 2429 | | 流通股本（百万股） | 2371 | | 流通股比例（%） | 97.61 | | 总市值（亿元） | 590.1 | | 流通市值（亿元） | 576.0 | [Table_Chart] 公司价格与沪深 300 走势比较 执业证书号：S0010524070001 邮箱：liyc@hazq.com 相关报告 1. 生 ...

[Table_StockNameRptType] 恒立液压（601100） 公司点评 业绩稳健发展，线性驱动项目未来可期 | [Table_Rank] 投资评级：买入（维持） | | | --- | --- | | 报告日期： | 2025-05-05 | | 570 收盘价（元） | 74.42 | | 近 12 个月最高/最低（元） | 99.47/41.55 | | 总股本（百万股） | 1340.82 | | 流通股本（百万股） | 1340.82 | | 流通股比例（%） | 100% | | 总市值（亿元） | 997.84 | | 流通市值（亿元） | 997.84 | [公司价格与沪深 Table_Chart] 300 走势比较 -30% -20% -10% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 恒立液压 沪深300 [分析师：张帆 Table_Author] 执业证书号：S0010522070003 邮箱：zhangfan@hazq.com ⚫ 投资建议 我们看好公司长期发展，根据 2024 年年报情况，修改之前盈利预测为： 2025-202 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a revenue of 803 million yuan for 2024, representing a year-on-year growth of 23.83%, with semiconductor business revenue reaching 249 million yuan, a significant increase of 199.28%. However, the net profit attributable to shareholders decreased by 30.71% to 80.16 million yuan [5][6] - In the first quarter of 2025, the company achieved a revenue of 152 million yuan, an increase of 83.16% compared to 83.05 million yuan in the same period of 2024 [5] - The company is focusing on optimizing its product structure and maintaining a strong growth trajectory in the semiconductor testing equipment sector, with significant advancements in key products such as DRAM aging test repair equipment and MEMS probe cards [6][7] Financial Summary - The company expects revenues for 2025, 2026, and 2027 to be 1.202 billion yuan, 1.580 billion yuan, and 1.979 billion yuan, respectively, with a downward adjustment in profit expectations due to a significant decline in panel revenue and a decrease in gross margin for semiconductor products [9] - The projected net profit attributable to shareholders for 2025, 2026, and 2027 is 177 million yuan, 235 million yuan, and 316 million yuan, respectively, with corresponding P/E ratios of 39.46X, 29.65X, and 22.12X [9][11]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's Q1 performance met expectations, with revenue growth slowing due to lower-than-expected sales from major clients and increased depreciation and R&D expenses impacting profit margins [1][5] - The company achieved a revenue of 26.6 billion yuan in 2024, a year-on-year increase of 35.02%, and a net profit attributable to shareholders of 3.001 billion yuan, up 39.52% year-on-year [1][7] - In Q1 2025, the company reported revenue of 5.768 billion yuan, a year-on-year increase of 1.40%, but a quarter-on-quarter decrease of 20.43%, with a net profit of 565 million yuan, down 12.39% year-on-year and 26.23% quarter-on-quarter [1][5] Financial Performance Summary - The company’s gross margin for 2024 was 20.80%, down 2.23 percentage points year-on-year, while the net profit margin was 11.28%, up 0.36 percentage points year-on-year [5] - For Q1 2025, the gross margin was 19.89%, down 2.53 percentage points year-on-year but up 0.08 percentage points quarter-on-quarter, with a net profit margin of 9.80%, down 1.54 percentage points year-on-year and 0.77 percentage points quarter-on-quarter [5] - The company’s operating expenses as a percentage of revenue for 2024 were 1.03% for sales, 2.33% for management, 4.60% for R&D, and 0.62% for financial expenses [5] Business Development Insights - The company is expanding into humanoid robot electric drive actuator business, leveraging its technical expertise in line control brake systems to enhance competitiveness in this field [6] - The company has established a dedicated electric drive division to accelerate business development and is integrating key technologies across its automotive and robotics sectors [6] - The platform strategy for products such as air suspension and robotic actuators is expected to create new growth opportunities for the company [7] Earnings Forecast - The company is projected to achieve net profits of 3.526 billion yuan, 4.333 billion yuan, and 5.468 billion yuan for the years 2025, 2026, and 2027, respectively, with corresponding P/E ratios of 26, 21, and 17 times [7][9]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's Q1 performance met expectations, with revenue growth slowing due to lower-than-expected sales from major clients. In 2024, the company achieved revenue of 26.6 billion yuan, a year-on-year increase of 35.02%, and a net profit attributable to shareholders of 3.001 billion yuan, up 39.52% year-on-year. In Q1 2025, revenue was 5.768 billion yuan, a year-on-year increase of 1.40%, but a quarter-on-quarter decrease of 20.43%, with a net profit of 565 million yuan, down 12.39% year-on-year and 26.23% quarter-on-quarter [3][4][5] Summary by Sections Financial Performance - In 2024, the company achieved a gross margin of 20.80%, down 2.23 percentage points year-on-year, and a net profit margin of 11.28%, up 0.36 percentage points year-on-year. In Q1 2025, the gross margin was 19.89%, down 2.53 percentage points year-on-year but up 0.08 percentage points quarter-on-quarter, while the net profit margin was 9.80%, down 1.54 percentage points year-on-year and 0.77 percentage points quarter-on-quarter [5][6] Business Development - The company is expanding its humanoid robot electric actuator business, leveraging its technical expertise in line control brake systems (IBS) to develop competitive products in the robotics field. The company has quickly gained customer recognition for its linear actuators and is expanding into rotary actuators and dexterous motors, establishing a platform product system [6][7] Investment Recommendations - The company is positioned as an excellent tier 0.5 platform component supplier, capitalizing on the growth of the new energy vehicle market. The ongoing platform strategy and new business areas such as air suspension and robotic actuators are expected to provide new growth points. The projected net profits for 2025, 2026, and 2027 are 3.526 billion yuan, 4.333 billion yuan, and 5.468 billion yuan, respectively, with corresponding P/E ratios of 26, 21, and 17 [7][9]

| [Table_BaseData] 收盘价（元） | 33.50 | | --- | --- | | 近 12 个月最高/最低（元） | 47.50/28.10 | | 总股本（百万股） | 209 | | 流通股本（百万股） | 194 | | 流通股比例（%） | 92.90 | | 总市值（亿元） | 70 | | 流通市值（亿元） | 65 | [公司价格与沪深 Table_Chart] 300 走势比较 可孚医疗（ [Table_StockNameRptType] 301087） 公司点评 产品丰富+渠道多元，收入增长持续稳健 | 投资评级：买入（维持） [Table_Rank] | | --- | | 报告日期： 2025-05-04 | -31% -16% -2% 13% 28% 5/24 8/24 11/24 2/25 可孚医疗 沪深300 [Table_Author] 分析师：谭国超 执业证书号：S0010521120002 邮箱：tangc@hazq.com 分析师：李婵 执业证书号：S0010523120002 邮箱：lichan@hazq.com [Table_CompanyRepo ...

——迎驾贡酒 24 年报&25Q1 点评 | 投资评级：买入（维持） [Table_Rank] | | | | --- | --- | --- | | 报告日期： | 2025-05-04 | | | [Table_BaseData] 收盘价（元） | | 43.92 | | 近 12 个月最高/最低（元） | | 80.19/43.90 | | 总股本（百万股） | | 800 | | 流通股本（百万股） | | 800 | | 流通股比例（%） | | 100.00 | | 总市值（亿元） | | 351 | | 流通市值（亿元） | | 351 | 迎驾贡酒（ [Table_StockNameRptType] 603198） 公司点评 | 系列酒与省外拖累 | | --- | [公司价格与沪深 Table_Chart] 300 走势比较 -50% -31% -12% 7% 26% 5/24 8/24 11/24 2/25 迎驾贡酒 沪深300 [Table_Author] 分析师：邓欣 执业证书号：S0010524010001 邮箱：dengxin@hazq.com 联系人：郑少轩 执业证书号：S001 ...

1 圣湘生物（ [Table_StockNameRptType] 688289） 公司点评 呼吸道检测持续高增长，并购拓展成长边界 | 投资评级：买入（维持） [Table_Rank] | | | | --- | --- | --- | | 报告日期： | 2025-05-04 | | | [Table_BaseData] 收盘价（元） | | 19.81 | | 近 12 个月最高/最低（元） | | 26.36/16.44 | | 总股本（百万股） | | 579 | | 流通股本（百万股） | | 579 | | 流通股比例（%） | | 100.00 | | 总市值（亿元） | | 115 | [公司价格与沪深 Table_Chart] 300 走势比较 其中，2025 年第一季度，公司实现收入 4.75 亿元，同比增长 21.62%；归母净利润 0.92 亿元，同比增长 13.22%，扣非净利润 0.90 亿元，同比增长 22.70%。 ➢ 事件点评 -30% -13% 4% 20% 37% 5/24 8/24 11/24 2/25 圣湘生物 沪深300 [Table_Author] 分析师：谭国超 ...

| | | 公司点评 ⚫ 投资建议：维持"买入" | 静待渠道改革见效 | | --- | ——三只松鼠 25Q1 点评 主要观点： ➢ 25Q1 收入符合市场预期。 ⚫ 收入：春节错期扰动 ➢ 分渠道看，线上面临高基数压力，预计营收增速同比持平。根据久谦 数据，公司 25Q1 猫京抖 GMV 合计同比下降 0.9%。线下渠道改革 顺 利 ， 预 计 同 比 实 现 双 位 数 增 长 。 去 除 春 节 影 响 ， 营 收 端 "24Q4+25Q1"合计同比增长 16.2%，仍处于快速增长。 ⚫ 利润：渠道费用投入阶段性加大 ➢ 25Q1 公司毛利率同比下降 0.66pct 至 26.74%，销售/管理/研发/财务 费率分别同比+2.41/+0.43/持平/-0.03pct。其中，毛利率下降与销售 费率上升，预计主因渠道改革导致费用投入力度加大；管理费率上升 预计主因研发中心转固导致折旧摊销费用上升。综上，公司归母净利 率同比下降 2.04pct 至 6.42%。 [Table_Author] 分析师：邓欣 执业证书号：S0010524010001 邮箱：dengxin@hazq.com 联系人：郑少轩 执 ...